Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy

Alina Sturdza 1 · Sandra Hofmann 2 · Marlene Kranawetter 2 · Stephan Polterauer 2,4 · Christoph Grimm 2 · Michael Krainer 3 · Christian Kirisits 1 · Richard Pötter 1 · Alexander Reinthaller 2,4 · Richard Schwameis 2

Abstract

Background and purpose Patients with recurrent cervical cancer (RecCC) who received definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT) as primary treatment are currently treated in our institution with palliative intent by chemotherapy (CHT) combined with bevacizumab (BEV). We aim to evaluate the risk of gastrointestinal (GI)/genitourinary (GU) fistula formation in these patients.

Materials and methods Data of 35 consecutive patients with RecCC treated initially with radiochemotherapy and IGABT were collected. Known and presumed risk factors associated with fistula formation were evaluated. Fistula rate was compared between patients receiving CHT or CHT+BEV.

Results Of the 35 patients, 25 received CHT and 10 patients received CHT+BEV. Clinical characteristics were comparable. Fistulae were reported in 6 patients: two fistulae (8%) in the CHT group, four (40%) in the CHT+BEV group. GU fistula occurred in the CHT+BEV group only (3/4). Of these 6 patients with fistulae, 5 (83%) had undergone previous invasive procedures after the diagnosis of RecCC and 1 patient had undergone pelvic re-irradiation; 3/6 patients had developed a local recurrence. No other risk factors for fistula formation were identified.

Conclusion In patients with RecCC after definitive radiochemotherapy including IGABT, the addition of BEV to CHT may increase the risk for GU fistula formation, particularly after invasive pelvic procedures. Future clinical studies are required to identify predictors for fistula formation to subsequently improve patient selection for the addition of BEV in the RecCC setting.

Keywords Avastin · Radiotherapy · Chemotherapy · Cervical cancer · Toxicity
For patients with locally advanced cervical cancer (LACC), concurrent radiochemotherapy including brachytherapy (BT) is the standard therapy, leading to good oncologic results [1–3]. The reported absolute risk of developing grade 3–4 (G3–4) genitourinary (GU) or gastrointestinal (GI) fistulae through definitive radiation therapy including standard BT with dose prescription to point A is around 9% (overall G3–4 toxicity 30%) [4]. Within the last few years, modern radiotherapy techniques have been introduced into the treatment of LACC. These include magnetic resonance (MR) image-guided adaptive brachytherapy (IGABT) [5] with dose prescription individualised to the target at the time of BT. In a recently published cohort of 731 patients, the overall actuarial rate of G3–4 GI and GU toxicity after definitive radiochemotherapy and IGABT was 11% at 5 years [6, 18]. A previous publication from our centre on 156 patients in whom systematic IGABT was performed reported only 2/156 fistula events [5]. Despite excellent overall local tumour control results, several series [5, 7, 8] still observed relatively high rates of distant recurrences after IGABT, especially in patients with advanced stage (stage III/IV) and/or nodal disease [6]. These distant metastases require cytotoxic treatment.

Patients with recurrent cervical cancer (RecCC), depending on the site of relapse (local, distant), have been treated by systemic chemotherapy (CHT), typically with paclitaxel-containing regimes. Since 2014, the use of bevacizumab (BEV) in combination with systemic CHT for the treatment of recurrent or metastatic cervical cancer has become common. It has been shown that the addition of BEV was associated with a significant increase in progression-free and overall survival [9]. However, it has also been reported that CHT+BEV is associated with an increased risk of fistula formation when compared to CHT alone in patients with cervical cancer [10], even in the absence of radiation treatment. In a subset analysis of the Gynecologic Oncology Group trial (GOG 240) published in abstract form [11], it was observed that among the patients who developed GI vaginal fistula, 100% had received prior pelvic radiation, some including standard brachytherapy. However, little is known about the risk factors for fistula formation in the presence of BEV. This study aims to evaluate whether patients with RecCC treated initially by concurrent radiochemotherapy and IGABT have an increased risk for GI and GU fistula formation after CHT+BEV treatment.

Materials and methods

Patients

Consecutive patients diagnosed with RecCC who were treated between 2009 and 2014 in our institution were enrolled in this study. Clinical data were obtained using available tumour databases and by electronic chart review. The 2009 International Federation of Gynecology and Obstetrics (FIGO) classification system was used [12]. Eligible patients had recurrence of a formerly locally advanced cervical cancer that had been initially treated by definitive concurrent radiochemotherapy including IGABT in our institution. Patients treated initially with surgery or those with primary metastatic disease were not eligible.

Tumour status was assessed, the presence of GU and GI fistula identified, and survival and follow-up times were recorded. Risk factors for fistula development including comorbidities (diabetes, arterial hypertension, peripheral vascular disease, thromboembolic events), previously performed bowel surgery, minor interventions/biopsy/major pelvic surgery after RecCC and number of treatment cycles were documented.

The primary endpoint was to document the frequency of fistula events in both groups (CHT or CHT+BEV) in this mono-institutional series.

The Ethics Committee of our institution gave approval prior to initiation of the study (IRB approval number: 1996/2015). All patients consented to treatment according to institutional guidelines, as well as to anonymized assessments and analysis of data and outcome of therapy. Records were anonymized and de-identified prior to analysis.
Treatment

Initial treatment

All patients received definitive concurrent radiochemotherapy. Radiotherapy consisted of external beam radiotherapy (EBRT) concurrent with weekly cisplatin-based CHT (usually cisplatin 5 × 40 mg/m² body surface area) and IGABT. The maximally allowed duration of radiation therapy was 50 days in total.

External beam radiotherapy

EBRT was delivered using three-dimensional conformal techniques or intensity-modulated radiation therapy. The clinical target volume (CTV) irradiated through EBRT consisted of the tumour, entire uterus, bilateral parametria, upper vagina (if no vaginal involvement had been present) and the pelvic lymph nodes. In case of lymph node involvement of the common iliac or para-aortic (PAN) lymph nodes (as diagnosed by positron-emission tomography/CT [PET-CT] or laparoscopic staging lymphadenectomy), para-aortic radiotherapy was performed. The prescribed dose was 45 Gy at 1.8 Gy per fraction. Grossly involved lymph nodes, if not surgically removed, were treated with an additional boost (range 55–60 Gy).

Image-guided adaptive brachytherapy

Systematically, MRI-based IGABT was performed in all patients diagnosed with LACC with definitive intent. The high-risk CTV (HRCTV) and/or the intermediate-risk CTV (IRCTV) was contoured according to Gyn GEC-ESTRO Recommendations I [13]. Organs at risk (OARs) were contoured: rectum, sigmoid colon and urinary bladder. Dose–volume histogram (DVH) parameters for the HRCTV, IRCTV and OARs were calculated and reported according to Gyn GEC-ESTRO Recommendations II [14]. Dose prescription for target and dose constraints for OARs were applied according to our institutional guidelines [5]. Our planning aim was ≥85 Gy to 90% of the HRCTV (D90). This total EQD2 (equivalent dose in 2 Gy per fraction) from EBRT and BT was calculated using an α/β of 10 Gy for tumour (EQD210) and 3 Gy for OARs (EQD23) [15].

Follow-up

All patients were followed-up in a joint programme by a gynaecologic oncologist and a radiation oncologist specialised in gynaecologic malignancies. Regular follow-up included clinical examination, blood analysis and imaging. Complete remission after initial treatment was defined as the absence of disease in the cervix (uterus), upper vagina, parametrium and regional lymph nodes, as verified by clinical examination, abdominal and thoracic imaging, and biopsy as appropriate. Patients were followed-up every 3 to 4 months for the first 3 years, every 6 months for the following 2 years and annually up to 10 years and beyond thereafter. Follow-up was performed at our institution using standardized questionnaires and assessment forms.

If recurrent disease was suspected, restaging by CT scans of the thorax and abdomen as well as MRI of the pelvis was performed. Whenever possible, recurrent disease was confirmed by biopsy and PET-CT was additionally performed.

Recurrence treatment

Chemotherapy/bevacizumab

Within this study, all patients were treated by either CHT or CHT+BEV. In addition, salvage surgery was performed in selected cases. CHT consisted of paclitaxel in combination with cisplatin (n = 18), with carboplatin (n = 2), or with topotecan (n = 5). Alternatively, selected patients received cisplatin in combination with topotecan (n = 9) or carboplatin with docetaxel (n = 1). CHT was administered until progression, complete response or treatment-limiting toxicity occurred. Starting 2013, most patients received BEV in addition to CHT (n = 10). Thereafter, patients were again followed-up according to the institution’s follow-up program. In a few cases, salvage surgery or radiotherapy of metastases was performed in the presence of oligometastases in lung, liver or periaortic nodes.

Statistical analysis

Time-to-event analyses were computed using the Kaplan–Meier method and log-rank test, with IBM SPSS 23.0 for MAC (SPSS 23.0, IBM Inc., Armonk, NY, USA). Time intervals for survival analyses were calculated from the date of biopsy to the date of event or last follow-up. Patients lost to follow-up were censored at the time of last follow-up.

Descriptive statistic values are given as mean (standard deviation, SD). T-tests and χ² tests were used to compare patients’ characteristics and risk factors for fistula formation between groups. P-values <0.05 were considered statistically significant. Overall survival was analysed using the log-rank test.

Results

A total of 35 patients were included in this study. Patients’ and treatment characteristics are shown in Table 1. There were no fistulae at the time of relapse diagnostic.
Table 1  Patient characteristics for the whole group (N = 35) and broken down by subsequent treatment, i.e. chemotherapy only or chemotherapy plus bevacizumab

| Variable                      | N total (%) | CHT (N = 25) | CHT+BEV (N = 10) |
|-------------------------------|-------------|--------------|------------------|
| **Initial stage**             |             |              |                  |
| IB                            | 4 (11)      | 3 (12)       | 1 (10)           |
| IIB                           | 18 (52)     | 15 (60)      | 3 (30)           |
| IIIA–IIB                      | 8 (22)      | 4 (16)       | 4 (40)           |
| IVA                           | 3 (9)       | 3 (12)       | 0                |
| IVB                           | 2 (6)       | 0            | 2 (20)           |
| **Histology**                 |             |              |                  |
| Squamous cell carcinoma       | 27 (77)     | 20 (80)      | 7 (70)           |
| Adenocarcinoma or adeno-squamous | 8 (23)     | 5 (20)       | 3 (30)           |
| **Grade**                     |             |              |                  |
| G1                            | 3 (9)       | 2 (8)        | 1 (10)           |
| G2                            | 14 (40)     | 9 (36)       | 5 (50)           |
| G3                            | 13 (37)     | 10 (40)      | 3 (30)           |
| Not evaluated                 | 5 (14)      | 4 (16)       | 1 (10)           |
| **Median age (years)**        | 51 (32–78)  | 53 (32–78)   | 49 (32–64)       |
| **ECOG**                      |             |              |                  |
| 0                             | 21 (60)     | 14 (56)      | 7 (70)           |
| 1                             | 12 (34)     | 10 (40)      | 2 (20)           |
| 2                             | 2 (6)       | 2 (4)        | 1 (10)           |
| **Comorbidities**             |             |              |                  |
| *Diabetes*                    |             |              |                  |
| Yes                           | 2 (6)       | 1 (4)        | 1 (10)           |
| No                            | 33 (94)     | 24 (96)      | 9 (90)           |
| *Hypertension*                |             |              |                  |
| Yes                           | 12 (34)     | 7 (28)       | 5 (50)           |
| No                            | 23 (66)     | 18 (72)      | 5 (50)           |
| *GI surgery*                  |             |              |                  |
| Yes                           | 2 appendectomy, 3 bowel resection (14) | 4 (16) | 1 bowel resection (10) |
| No                            | 30 (86)     | 21 (84)      | 9 (90)           |
| *Thromboembolic event*        |             |              |                  |
| Yes                           | 6 (17)      | 2 (8)        | 4 (40)           |
| No                            | 29 (83)     | 23 (92)      | 6 (60)           |
| **Primary treatment**         |             |              |                  |
| EBRT dose (Gy)                | 45          | 45           | 45               |
| EBRT pelvis (n)               | 20          | 15           | 5                |
| EBRT extended-field (n)       | 15          | 10           | 5                |
| EBRT IMRT/VMAT (n)            | 6 (17)      | 0            | 6 (17)           |
| EBRT 3D conformal (n)         | 29 (83)     | 29 (83)      | 6 (17)           |
| BT IC only (n)                | 4 (14)      | 4 (16)       | 0                |
| BT IC/interstitial            | 31 (86)     | 21 (84)      | 10 (100)         |
| **Surgical LN staging**       |             |              |                  |
| Yes                           | 26 (74)     | 20 (80)      | 6 (60)           |
| **Response rate at initial treatment** |         |              |                  |
| Complete                      | 25 (71)     | 18 (72)      | 7 (70)           |
| Partial                       | 10 (29)     | 7 (28)       | 3 (30)           |
| **Type of recurrence**        |             |              |                  |
| Local/pelvic                  | 7 (20)      | 5 (20)       | 2 (20)           |
| Distal                        | 20 (57)     | 13 (52)      | 7 (70)           |
| Combination                   | 8 (23)      | 7 (28)       | 1 (10)           |
CHT was received by 25 patients and 10 patients received CHT+BEV. Patient characteristics and treatment modalities in the both groups were similar. All 10 patients in the CHT+BEV group had undergone interstitial IGABT as opposed to 21/25 in the CHT group ($p = 0.18$).

Table 2 provides treatment details of the therapy at first diagnosis and the number of events analysed according to the type of treatment at recurrence. No statistically significant difference in radiation dose (90.4 Gy vs. 89.4 Gy, $p = 0.353$) or number of CHT cycles at RecCC (5.1 vs. 6.4, $p = 0.403$) was observed between treatment groups.

A total of six fistulae were recorded (patient tumour and treatment details in Table 3: P1-6). In the CHT+BEV group, a significantly higher rate of fistula formation (4/10 patients, 40%) was observed compared to the CHT only group (2/25 patients, 8%; $p = 0.043$).

GU fistula formation was noticed only in the CHT+BEV group (3/10 patients), of which two were grade 2 and one was grade 3 requiring surgical intervention [16]. Additionally, a grade 3 rectovaginal fistula was documented in this group (P2). In the CHT only group, both events were rectovaginal fistula grade 3. For all patients with G3 rectovaginal fistula a functional colostomy was performed. For the G3 GU fistula, an ileal conduit was necessary.

At the time of recurrence, 2 patients had persistent local disease (incomplete remission), 1 patient had local recurrence (which was treated with palliative re-irradiation) and 3 patients had systemic recurrence (Table 3).

All 6 patients with fistula formation had undergone an invasive procedure or palliative pelvic radiation prior to or during the systemic palliative treatment (Table 3). In the CHT group the events occurred subsequent to a posterior vaginal wall biopsy (P5) and after pelvic re-irradiation (P3). In this group, a further 10 of the remaining 23 patients had undergone an invasive procedure but did not develop fistula (Table 1). In the CHT+BEV group, 4/4 patients with events (100%) had undergone at least a minimally invasive procedure (i.e. ureter stenting) and only 1/6 patients (17%) did not develop an event after an invasive procedure.

We found no association between radiation dose to the target or the reported DVH parameters for OARs and the rate of fistula (Table 4).

Within the cohort, median follow-up was 11 months (range 0–50 months) and overall survival time from the date of diagnosis of RecCC was 8 months (2–27 months) and 26 months (5–87 months) from diagnosis of primary disease. Fistula formation had no significant impact on overall survival ($p = 0.317$).

### Table 1

Patient characteristics for the whole group ($N = 35$) and broken down by subsequent treatment, i.e. chemotherapy only or chemotherapy plus bevacizumab (Continued)

| Variable | $N$ total (%) | CHT ($N = 25$) | CHT+BEV ($N = 10$) |
|----------|---------------|----------------|-------------------|
| Pelvic minor intervention/surgery/biopsy after RecCC | | | |
| Yes | 17 (49) | 12 (48) | 5 (50) |
| No | 18 (51) | 13 (52) | 5 (50) |
| Response rate (to treatment for recurrence) | | | |
| Complete | 7 (20) | 5 (20) | 2 (20) |
| Partial | 5 (14.3) | 2 (8) | 3 (30) |
| Stable disease | 4 (11.4) | 3 (12) | 1 (10) |
| Progressive disease | 15 (42.9) | 11 (44) | 4 (40) |
| Unknown | 4 (11.4) | 4 (16) | 0 |
| Median follow-up from recurrence (months) | 11 (0–50) | 11 (0–50) | 11 (5–28) |
| Median follow-up from recurrence to event (months) | 8 (2–27) | 11 (2–20) | 8 (5–27) |
| Median follow-up from diagnosis (months) | 26 (5–87) | 22 (5–87) | 38 (15–48) |
| Alive with no evidence of disease | 5 (14.3) | 4 (16) | 1 (10) |
| Alive with stable disease | 7 (20.0) | 4 (16) | 3 (30) |
| Alive with progressive disease | 6 (17.1) | 4 (16) | 2 (20) |
| Died intercurrently | 1 (2.9) | 0 | 1 (10) |
| Died of cancer | 16 (45.7) | 13 (52) | 3 (30) |

CHT chemotherapy, BEV bevacizumab, ECOG Eastern Cooperative Oncology Group, GI gastrointestinal, EBRT external beam radiotherapy, IMRT intensity-modulated radiotherapy, VMAT volumetric-modulated arc therapy, LN lymph node, RecCC recurrent cervical cancer, BT IC intracavitary only brachytherapy
Table 2  Treatment characteristics at the time of recurrence, dose–volume parameters (DVH) at the time of the initial definitive treatment and number of events based on the type of treatment for recurrent disease

| Variable                  | CHT (n = 25) | CHT +BEV (n = 10) |
|---------------------------|--------------|-------------------|
| **Fistulae**              |              |                   |
| Total                     | 2 (8%)       | 4 (40%)           |
| Rectovaginal              | 2            | 1                 |
| Vesicovaginal             | 0            | 3                 |
| Mean (SD) no. of treatment cycles |            |                   |
| CHT cycles                | 5.1 (1.9)    | 6.4 (4.5)         |
| BEV cycles                | –            | 5.4 (3.6)         |
| **BT application type**   |              |                   |
| IC                        | 4            | 0                 |
| IC/IS                     | 21           | 10                |
| **Radiation dose (Gy)**   |              |                   |
| Mean D_{90} HRCTV         | 90.4 (7.6)   | 89.4 (5.7)        |
| Mean D_{0.1cc} rectum     | 73.5 (11.3)  | 73.1 (8.5)        |
| Mean D_{2cc} rectum       | 63.6 (7.7)   | 63.4 (6.9)        |
| Mean D_{0.1cc} sigmoid     | 78.0 (13.9)  | 80.0 (7.2)        |
| Mean D_{2cc} sigmoid       | 64.7 (7.8)   | 66.7 (5.8)        |
| Mean D_{0.1cc} bladder     | 100.3 (13.3) | 100.5 (7.7)       |
| Mean D_{2cc} bladder       | 79.8 (8.4)   | 82.4 (6.0)        |
| Mean D_{0.1cc} bowel       | 58.5 (29.5)  | 65.4 (37.4)       |
| Mean D_{2cc} bowel         | 52.6 (26.3)  | 55.1 (30.1)       |

CHT chemotherapy, BEV bevacizumab, BT brachytherapy, HRCTV high-risk clinical target volume, D90 dose to 90% of the HRCTV, SD standard deviation, IC intracavitary only, IC/IS intracavitary and interstitial brachytherapy, D2cc dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)

**Discussion**

In this study, patients receiving a combination of CHT and BEV for the treatment of RecCC had a significantly higher risk for fistula formation than patients receiving CHT alone (40 vs. 8%). We observed a notably higher rate of GU fistula in patients treated with CHT+BEV (30% vs. none). The rate of rectovaginal fistula was similar in the two groups (10 vs. 8%).

Previously published studies reported an overall fistula (>grade 2) formation rate of 8.6% (GI vaginal) and 3.2% GI perforation in 218 patients with preliminary metastatic or recurrent cervical cancer treated in the CHT+BEV arm [17] of the GOG 240 study (first data freeze). Furthermore, the rate of fistula (any grade) formation was even higher (12.6%) during CHT+BEV treatment if only patients with prior radiochemotherapy were considered [11]. Overall, GOG 240 reported an increased incidence of 6% of fistula formation (second data freeze) [9]. It is not clear how many patients had received definitive radiochemotherapy including IGABT in the GOG 240 cohort. In our cohort, only patients who received definite IGABT plus radiochemotherapy as initial treatment were included. Therefore, our cohort is the first one comparing CHT and CHT+BEV in LACC patients previously treated with definitive radiochemotherapy and IGABT.

All patients who developed fistulae in our cohort had undergone a minor intervention (5/6, 83%; repeated ureter stenting, biopsy or pelvic re-irradiation) or a major pelvic surgery (1/6, 17%). This is in accordance with the observation of Feddock el al. [19], who associated pelvic radiation and invasive procedures with 8.2% fistula formation, even in the absence of CHT ± BEV. In the CHT group, 43% (10/23) of the non-event patients had undergone an intervention, while in the CHT+BEV only group, 17% (1/6) had undergone an invasive pelvic procedure and did not develop a fistula. This may suggest that BEV in the presence of an invasive pelvic procedure may trigger GU fistula formation. There are case reports in literature suggesting that a combination of perioperative BEV administration and an invasive procedure could result in fistula formation. Aortoesophageal fistula rupture or colovesical fistula during treatment including BEV due to metastatic colorectal cancer have been reported in case studies [25]. One other report describes two late-onset pulmonary fistulae after resection of pulmonary metastasis from colorectal cancer following perioperative CHT with BEV [26]. An increased risk of bowel perforation or fistula formation for patients with recurrent epithelial ovarian cancer treated with BEV has been observed [24, 27, 28].

Although not statistically significant due to the limited number of patients and events, one may observe the fact that 3/6 patients with fistulae had a local recurrence (2 patients...
Table 3  Tumour and treatment characteristics of the patients with events (fistula formation)

| Patient no. (P1–6) | FIGO stage | N status | Tumour width at BT (mm) | Applicator type at BT | D90 HRCTV (Gy) | D0.1cc rectum (Gy) | D2cc rectum (Gy) | D0.1cc bladder (Gy) | D2cc bladder (Gy) | Complete remission after definitive treatment | Type of first recurrence | Recurrence therapy | Type of fistula (grade) | Type of interventions or pelvis surgery after recurrence | Type of intervention |
|-------------------|------------|----------|-------------------------|-----------------------|----------------|-------------------|----------------|-------------------|----------------|-------------------------------------------------|-----------------------|-------------------|---------------------|-------------------------------------------------|----------------------|
| 1                 | IIIB       | pN0      | 80                      | Interstitial          | 87.4           | 76                | 62              | 110               | 94              | No                                              | Persistent local disease | CHT + BEV         | G2 vesico-vaginal | Yes                              | Repeated ureter stenting                |
| 2                 | IIIB       | pN0      | 60                      | Interstitial          | 93             | 78                | 66              | 102               | 85              | Yes                                             | Systemic               | CHT + BEV         | G3 recto-vaginal | Yes                              | Major pelvic surgery                  |
| 3                 | IIIB       | pN1      | 50                      | Interstitial          | 93             | 74                | 64              | 99               | 78              | Yes                                             | Local                  | CHT               | G3 recto-vaginal | No                               | Pelvic re-irradiation                          |
| 4                 | IIIB       | cN1      | 50                      | Interstitial          | 93             | 79                | 70              | 104               | 84              | No                                              | Persistent local + systemic disease | CHT + BEV         | G2 vesico-vaginal | Yes                              | Repeated ureter stenting                |
| 5                 | IIIB       | cN1      | 40                      | Interstitial          | 84.3           | 84                | 76              | 98               | 76              | Yes                                             | Systemic               | CHT               | G3 recto-vaginal | Yes                              | Biopsy posterior vaginal wall              |
| 6                 | IIIB       | pN1      | 35                      | Interstitial          | 97.6           | 79                | 64              | 98               | 75              | Yes                                             | Systemic               | CHT + BEV         | G3 vesico-vaginal | Yes                              | Repeated ureter stenting                |

CHT chemotherapy, BEV bevacizumab, BT brachytherapy, HRCTV high-risk clinical target volume, FIGO Federation of Gynecology and Obstetrics, D90 dose to 90% of the HRCTV, D0.1cc dose to 0.1cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder), D2cc dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)
never achieved complete local remission and 1 had a local recurrence).

We could not detect any association between comorbidities, radiation dose, performance status or previously performed bowel surgery prior to the diagnosis of RecCC and a higher rate of fistula formation. Our findings are in accordance with previously published reports [20]. In a study including 30 patients with FIGO stage IV A (with bladder or/and rectal infiltration) undergoing radiochemotherapy, the 5-year fistula-free survival rate was 64%, but no prognostic variables were identified. Although all the patients in the CHT +BEV group underwent interstitial IGABT as opposed to 84% in the CHT group, the use of interstitial implants is not statistically correlated to the occurrence of fistula when BEV is added to the treatment of RecCC ($p = 0.18$). Moreover, recent literature shows that primarily use of advanced IGABT, especially interstitial implants, does not increase late toxicity when compared to intracavitary therapy only [18].

Recent studies suggest that only intermediate- and high-risk RecCC patients show a survival benefit when receiving CHT+BEV [21]. These patients have 2–3 (intermediate-) and 4–5 (high-risk) risk factors from: black race, performance status 1, pelvic disease, prior cisplatin and progression-free interval <365 days. Hence, patient selection is crucial with respect to side effects and complications. Several approaches were performed to identify biomarkers to predict the effect of BEV on an individual basis [22]. However, no predictive biomarker has been established thus far.

CHT+BEV is administered to RecCC patients without curative intent. The quality of life in this palliative setting is of particular importance and should have a substantial influence on the selection of therapy. Interestingly, while GOG 240 reported an increased rate of fistula in the CHT+BEV group, the quality of life was not decreased in this group. Other reports show that fistula formation leads to a substantial reduction in quality of life [23]. Therefore, patient-reported outcomes, as used in GOG 240, might not be appropriate to determine the detrimental effect of fistula formation on quality of life.

Based on our observations, we suggest that when facing persistent disease or local recurrence, with or without systemic disease, caution should be used in prescribing CHT+BEV. This combination should be offered only after thoroughly informing the patients about the high probability of developing fistula, especially GU fistula. Prudence should also be used when facing ureteral stent change or other pelvic interventions, which are common in patients with RecCC.

Admittedly, the shortcomings of this study have to be considered. This was a retrospective data analysis of a small patient cohort from a single institution. The limited number of patients included in this report impaired statistical analysis and multivariate models were not feasible. However, given the lack of published data and increasing number of patients who are possibly candidates for this treatment, we want to raise awareness about the potential risks of using BEV in addition to CHT in the setting of pelvic RecCC and related interventions.

### Table 4: Mean radiation dose for HRCTV and OARs according to fistula status (dose–volume parameters [DVH] patients and Gy)

| Variable                                      | Fistula | No fistula | $p$-value |
|-----------------------------------------------|---------|------------|-----------|
| CHT (absolute number of cycles)               | 2       | 23         | 0.043a    |
| CHT + BEV (absolute number of cycles)         | 4       | 6          | –         |
| Mean HRCTV $D_{90}$ (%)                       | 92.1 (5.0) | 89.7 (7.4) | 0.353b    |
| Mean $D_{0.1cc}$ rectum (%)                   | 78.0 (4.6) | 72.4 (11.1) | 0.060b    |
| Mean $D_{0.1cc}$ bladder (%)                  | 62.8 (7.8) | 66.9 (3.6) | 0.066b    |
| Mean $D_{0.1cc}$ sigmoid (%)                  | 100.2 (12.6) | 101.2 (7.9) | 0.806b    |
| Mean $D_{0.1cc}$ bowel (%)                    | 82.1 (6.7) | 80.2 (8.1) | 0.551b    |
| Mean $D_{0.1cc}$ sigmoid (%)                  | 69.3 (12.5) | 80.5 (11.6) | 0.084b    |
| Mean $D_{0.1cc}$ bowel (%)                    | 59.4 (8.8) | 66.5 (6.4) | 0.108b    |
| Mean $D_{0.1cc}$ bowel (%)                    | 69.2 (20) | 57 (16)    | 0.193b    |
| Mean $D_{0.1cc}$ bowel (%)                    | 58 (9)   | 53 (10)    | 0.278b    |
| No. of CHT cycles (%)                         | 5.2 (2.2) | 5.6 (3.0)  | 0.715b    |
| No. of BEV cycles (%)                         | 3.8 (1.7) | 6.5 (4.3)  | 0.200b    |
| CHT chemotherapy, BEV bevacizumab, HRCTV high-risk clinical target volume, $D_{90}$ dose to 90% of the HRCTV, OAR organ at risk, $D_{0.1cc}$ dose to 0.1cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder), $D_{2cc}$ dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)

$a$χ$^2$ test

$b$ $t$-test
Conclusion

Until larger studies are available, based on our observations in this small cohort, and given the overall survival benefit [9], CHT+BEV should probably be offered mainly to patients with local control and systemic recurrences. Future clinical studies are required to identify predictive and prognostic factors for fistula formation, in order to improve patient selection for CHT+BEV in the setting of RecCC.

Acknowledgements

Open access funding provided by Medical University of Vienna.

Conflict of interest

A. Reinthaller and R. Schwameis declare that they have no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Perez CA, Grigsby PW, Chao KS, Mutch DG, Lockett MA (1998) Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 41:307–317
2. Eifel PJ, Jhiangran A, Brown J, Levenback C, Thomas H (2006) Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer 16:1106–1111
3. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of clinical oncology: official journal of the American Society of. J Clin Oncol 26:5802–5812
4. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS et al (2011) The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 117:948–956
5. Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123
6. Sturdy A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R et al (2016) Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. doi: 10.1016/j.radonc.2016.03.011
7. Gill BS, Kim H, Houser CJ, Kelley JL, Sukumvanich P, Edwards RP et al (2015) MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. Int J Radiat Oncol Biol Phys 91:540–547
8. Castelnuovo-Marchand P, Chargari C, Maroun P, Dumas I, Del Campo ER, Cao K et al (2015) Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol 139:288–294
9. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743
10. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Home-sley HD et al (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. Journal of clinical oncology: official journal of the American Society of. Clin Oncol 32:1210–1217
11. Willmott LJ (2014) Gastrointestinal and Genitourinary Fistulae in Women Treated with Chemotherapy with and without Bevacizumab for Advanced and Recurrent Cervical Cancer. International Gynecologic Cancer Society; Melbourne (A NRG Oncology – Gynecologic Group Ancillary Data Study 15th Biennial Meeting of the International Gynecologic Cancer Society)
12. Benedet JL, Bender H, Jones H 3rd, Ngsan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209–262
13. Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J et al (2005) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235–245
14. Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiol Oncol 78:67–77
15. Bentzen SM, Dorr W, Gahbauer R, Howell RW, Joiner MC, Jones B et al (2012) Bioeffect modeling and equieffective dose concepts in radiation oncology – terminology, quantities and units. Radiol Oncol 105:266–268
16. CTEP (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
17. Tewari KS (2014) Abstract LBA26 – final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: a NRG oncology – Gynecologic Oncology Group Study. European Society for Medical Oncology, Madrid
18. Fokdal L, Sturdy A, Mazeron R, Haie-Meder C, Tan LT, Gillham C et al (2016) Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiol Oncol. doi:10.1016/j.radonc.2016.03.020
19. Feddock J, Randall M, Kudrimoti M, Baldwin L, Shah P, Weiss H et al (2014) Impact of post-radiation biopsies on development of fistulas in patients with cervical cancer. Gynecol Oncol 133:263–267
20. Biewenga P, Mutsaers MA, Stalpers LJ, Buist MR, Schilthuis MS, van der Velden J (2010) Can we predict vesicovaginal or rectovaginal fistula formation in patients with stage IV A cervical cancer? Int J Gynecol Cancer 20:471–475
21. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ 3rd, Poveda A et al (2015) Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG oncology/GOG Study, Clin Cancer Res 21:5480–5487
22. Gonzalez-Vacarezza N, Alonso I, Arroyo G, Martinez J, De Andres F, Llarena A et al (2016) Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen. Drug Metabol Personal Ther. doi: 10.1515/dmpt-2015-0027
23. Mohr S, Brandner S, Mueller MD, Dreher EF, Kuhn A (2014) Sexual function after vaginal and abdominal fistula repair. Am J Obstet Gynecol 211:74.e1–74.e6.

24. Cohn DE, Kim KH, Resnick KE, O’Malley DM, Straughn JM Jr. (2011) At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29:1247–1251.

25. Koda T, Koike J, Masuhara H, Kurihara A, Shiokawa H, Ushigome M et al (2016) A case of aortoesophageal fistula rupture due to descending thoracic aortic dissection with recurrent colon cancer during chemotherapy containing bevacizumab. Gan To Kagaku Ryoho 43(12):1815–1817.

26. Kanzaki R, Shintani Y, Inoue M, Kawamura T, Funaki S, Minami M, Okumura M (2017) Late-onset pulmonary fistula after resection of pulmonary metastasis from colorectal cancer following perioperative chemotherapy with bevacizumab. Ann Thorac Cardiovasc Surg. doi:10.5761/atcs.cr.16-00117.

27. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O’Malley DM (2010) Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118(1):47–51.

28. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homsley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 32(12):1210–1217. doi:10.1200/JCO.2013.53.6524.